Medchemexpress/ST 2825/HY-50937/1mg_蚂蚁淘，【正品极速】生物医学科研用品轻松购|ebiomall 蚂蚁淘商城

商品信息

联系客服

郑重提醒：

无质量问题不接受退换货，下单前请仔细核对信息。

下单后请及时联系客服核对商品价格，订单生效后再付款。

Medchemexpress/ST 2825/HY-50937/1mg

品牌 /

MedChemExp

货号 /

HY-50937-10mM*1mLinDMSO

官网地址

美元价：

登录查看

(友情提示：该价格仅为参考，欢迎联系客服询价！)

数量：

免费咨询热线

4000-520-616

商品介绍售后保障相关文章商品咨询

联系客服

ST2825isaMyD88homodimerizationinhibitor.

CustomerValidation

•Gut.2017Sep12.pii:gutjnl-2017-314098.
•ACSNano.2015Oct27;9(10):10498-515.
•BrJPharmacol.2015Jun;172(12):3159-76.
•ExpNeurol.2017May18;295:23-35.
•SciRep.2017Nov17;7(1):15797.
•SciRep.2017Mar17;7:44822.

•PLoSOne.2014Jul18;9(7):e100985.
•BrainRes.2016Jul15;1643:130-9.
•AnticancerRes.2017Nov;37(11):6203-6209.
•MolMedRep.2015Jul;12(1):895-904.
•GenetMolRes.2016Mar4;15(1):15016826.

Description	ST2825isaMyD88homodimerizationinhibitor.
IC₅₀&Target	MyD88^[1]
InVitro	ST2825blocksIL-1R/TLRsignalingbyinterferingwithMyD88homodimerization.ST2825inhibitsthisinteractioninaconcentration-dependentmannerwith~40%inhibitionofdimerizationat5μMST2825and80%inhibitionat10μMST2825^[1].
InVivo	ST2825dose-dependentlyinhibitsIL-1β-inducedproductionofIL-6intreatedmiceafteroraladmiNISTration.TheanimalsareadministeredorallywiththeappropriatevehiclesorST2825atdosesrangingfrom50to200mg/kg,5minpriortoi.p.injectionwith20μg/kgIL-1β.ST2825exertesasignificantinhibitionofIL-1β-stimulatedproductionofIL-6at100and200mg/kg^[1].
References	[1].LoiarroM,etal.Pivotaladvance:inhibitionofMyD88dimerizationandrecruitmentofIRAK1andIRAK4byanovelpeptidomimeticcompound.JLeukocBiol.2007Oct;82(4):801-10. [2].FantòN,etal.Design,Synthesis,andInVitroActivityofPeptidomimeticInhibitorsofMyeloidDifferentiationFactor88.JMedChem.2008Mar13;51(5):1189-202. [3].VanTassellBW,etal.PharmacologicInhibitionofMyeloidDifferentiationFactor88(MyD88)PreventsLeftVentricularDilationandHypertrophyAfterExperimentalAcuteMyocardialInfarctionintheMouse.JCardiovascPharmacol.2010Apr;55(4):385-90. [4].ZhangHS,etal.Inhibitionofmyeloiddifferentiationfactor88(MyD88)byST2825providesneuroprotectionafterexperimentaltraumaticbraininjuryinmice.BrainRes.2016Jul15;1643:130-9. [5].WangN,etal.Myeloiddifferentiationfactor88isup-regulatedinepilepticbrainandcontributestoexperimentalseizuresinrats.ExpNeurol.2017Sep;295:23-35.

PreparingStockSolutions

ConcentrationVolumeMass	1mg	5mg	10mg

1mM	1.6906mL	8.4529mL	16.9059mL
5mM	0.3381mL	1.6906mL	3.3812mL
10mM	0.1691mL	0.8453mL	1.6906mL

Pleaserefertothesolubilityinformationtoselecttheappropriatesolvent.

CellAssay
^[1]

ST2825isdissolvedinDMSOandstored,andthendilutedwithappropriatemedia(DMSO0.1%)beforeuse^[1].

HeLacellsareseededat10⁵cells/mLina96-welltissue-cultureplate.Afterincubatingovernight,themediumisdiscarded,andthecellsareaddedwithtissueculturemedium,10%FBS,containingST2825atconcentrationsrangingfrom0.1to10μMandDMSOat0.1%finalconcentration.Thecellsareincubatedfor6and18handthenaddedwiththeyellowXTT(0.3mg/mL)forfurther2hofincubation.Attheendoftheincubationperiods,reactionsarequantifiedbyusingaSirioSSeacmicroplatereader^[1].MCEhasnotindependentlyconfirmedtheaccuracyofthesemethods.Theyareforreferenceonly.

AnimalAdministration
^[1]

ST2825isadministeredorallyas0.5%sUSPensionincarboxymethylcellulose(CMC)^[1].

Mice^[1]
Mice(femaleC57Bl/6)aredividedintoexperimentalgroupsof15mice.Theyareinjectedi.p.withsaline(controlanimals)orrecombinantmurineIL-1β(20μg/kg).Atime-courseanalysisofIL-6productionestablishedthatthepeakofcytokineisreached2hafterIL-1βinjection.ST2825,administeredorallyas0.5%suspensionincarboxymethylcellulose(CMC)orCMCalone,issuppliedtotheexperimentalmicegroups.TwohoursafterIL-1βinjection,theanimalsarekilled,andseraarecollectedtoassayIL-6levels.Mice,whicharetreatedorallywith100and200mg/kgST2825,showslowerlevelsofIL-6versusCMC-treatedmice.MCEhasnotindependentlyconfirmedtheaccuracyofthesemethods.Theyareforreferenceonly.

References

[1].LoiarroM,etal.Pivotaladvance:inhibitionofMyD88dimerizationandrecruitmentofIRAK1andIRAK4byanovelpeptidomimeticcompound.JLeukocBiol.2007Oct;82(4):801-10.
[2].FantòN,etal.Design,Synthesis,andInVitroActivityofPeptidomimeticInhibitorsofMyeloidDifferentiationFactor88.JMedChem.2008Mar13;51(5):1189-202.
[3].VanTassellBW,etal.PharmacologicInhibitionofMyeloidDifferentiationFactor88(MyD88)PreventsLeftVentricularDilationandHypertrophyAfterExperimentalAcuteMyocardialInfarctionintheMouse.JCardiovascPharmacol.2010Apr;55(4):385-90.
[4].ZhangHS,etal.Inhibitionofmyeloiddifferentiationfactor88(MyD88)byST2825providesneuroprotectionafterexperimentaltraumaticbraininjuryinmice.BrainRes.2016Jul15;1643:130-9.
[5].WangN,etal.Myeloiddifferentiationfactor88isup-regulatedinepilepticbrainandcontributestoexperimentalseizuresinrats.ExpNeurol.2017Sep;295:23-35.

MolecularWeight

591.51

Formula

C₂₇H₂₈Cl₂N₄O₅S

CASNo.

894787-30-5

Storage

Powder	-20°C	3years
	4°C	2years
Insolvent	-80°C	6months
	-20°C	1month

Shipping

RoomtemperatureincontinentalUS;mayvaryelsewhere

Solvent&Solubility

10mMinDMSO

ST2825isdissolvedinDMSO.ST2825solution(0.5μL)isadministeredviaintracerebroventricular(ICV)injectionat15minpost-injury,usinga1μLHamiltonmicrosyringe^[4].
ST2825isdissolvedin10%dimethylsulfoxidein0.1MPBS^[5].

*"<1 mg/ml"="" means="" slightly="" soluble="" or="" insoluble.="" "≥"="" means="" soluble,="" but="" saturation="">

References

[1].LoiarroM,etal.Pivotaladvance:inhibitionofMyD88dimerizationandrecruitmentofIRAK1andIRAK4byanovelpeptidomimeticcompound.JLeukocBiol.2007Oct;82(4):801-10.
[2].FantòN,etal.Design,Synthesis,andInVitroActivityofPeptidomimeticInhibitorsofMyeloidDifferentiationFactor88.JMedChem.2008Mar13;51(5):1189-202.
[3].VanTassellBW,etal.PharmacologicInhibitionofMyeloidDifferentiationFactor88(MyD88)PreventsLeftVentricularDilationandHypertrophyAfterExperimentalAcuteMyocardialInfarctionintheMouse.JCardiovascPharmacol.2010Apr;55(4):385-90.
[4].ZhangHS,etal.Inhibitionofmyeloiddifferentiationfactor88(MyD88)byST2825providesneuroprotectionafterexperimentaltraumaticbraininjuryinmice.BrainRes.2016Jul15;1643:130-9.
[5].WangN,etal.Myeloiddifferentiationfactor88isup-regulatedinepilepticbrainandcontributestoexperimentalseizuresinrats.ExpNeurol.2017Sep;295:23-35.

Purity:99.51%

SelectBatch: